(Q52527345)

2 May 2018

title

Effects of long-term administration of the antiepileptic drug--sodium valproate upon the ultrastructure of hepatocytes in rats. (English)

1 reference

2 May 2018

author name string

M E Sobaniec-Lotowska

series ordinal

1

1 reference

2 May 2018

publication date

1 August 1997

1 reference

2 May 2018

Experimental and Toxicologic Pathology

published in

1 reference

2 May 2018

volume

49

1 reference

2 May 2018

issue

3-4

1 reference

2 May 2018

page(s)

225-232

1 reference

2 May 2018

Use of Valproic Acid in Treatment of Infantile Spasms

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Valproate-induced hyperammonaemia in two epileptic identical twins

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Valproate-induced hepatic steatogenesis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Carnitine deficiency and hyperammonemia associated with valproic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Valproic acid amide in the treatment of affective and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Fatal liver failure in 16 children with valproate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme A metabolism by cotreatment with pantothenate and carnitine in developing mice: possible clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

CoA esters of valproic acid and related metabolites are oxidized in peroxisomes through a pathway distinct from peroxisomal fatty and bile acyl-CoA beta-oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

Acute liver disease associated with sodium valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0940-2993%2897%2980015-2

7 January 2021

10.1016/S0940-2993(97)80015-2

Identifiers

DOI

1 reference

2 May 2018

1 reference

2 May 2018